EyePoint (EYPT) Share-based Compensation (2010 - 2026)
EyePoint (EYPT) reported Share-based Compensation of $58.3 million for Q1 2026, up 6356.26% on a YoY basis from $903000.0 in Q1 2025, and up 2464.89% sequentially from $2.3 million in Q4 2025.
EyePoint (EYPT) Share-based Compensation (2010 - 2026) Analysis & Trends
EyePoint (EYPT) has 17 years of Share-based Compensation data on file, last reported at $58.3 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 6356.26% year-over-year to $58.3 million; the trailing twelve-month figure through Mar 2026 stood at $58.3 million (up 260.52% YoY), and the FY2025 full-year result was $21.3 million, down 42.03% from the prior year.
- Share-based Compensation grew to $58.3 million in Q1 2026, from $2.3 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $58.3 million in Q1 2026 to a low of -$8.5 million in Q4 2023.
- A 5-year average of $6.2 million and a median of $3.2 million in 2022 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation surged 67120.0% in 2022 and plunged 351.92% in 2023, its largest moves.
- Tracing EYPT's Share-based Compensation over 5 years: stood at $3.4 million in 2022, then sank by 351.92% to -$8.5 million in 2023, then soared by 193.3% to $7.9 million in 2024, then slumped by 71.23% to $2.3 million in 2025, then soared by 2464.89% to $58.3 million in 2026.
- Business Quant data shows EYPT's Share-based Compensation at $58.3 million in Q1 2026, $2.3 million in Q4 2025, and -$132000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | EyePoint | 358.61 Mn | 136.07 Mn | 168,000.00 | 58.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58.30 Mn |
| Mar 31, 2026 | 58.30 Mn |
| Dec 31, 2025 | 2.27 Mn |
| Dec 31, 2025 | 2.27 Mn |
| Sep 30, 2025 | -132,000.00 |
| Sep 30, 2025 | -132,000.00 |
| Jun 30, 2025 | 6.43 Mn |
| Jun 30, 2025 | 6.43 Mn |
| Mar 31, 2025 | 903,000.00 |
| Mar 31, 2025 | 903,000.00 |
| Dec 31, 2024 | 7.90 Mn |
| Dec 31, 2024 | 7.90 Mn |
| Sep 30, 2024 | 7.45 Mn |
| Sep 30, 2024 | 7.45 Mn |
| Jun 30, 2024 | -78,000.00 |
| Jun 30, 2024 | -78,000.00 |
| Mar 31, 2024 | 12.70 Mn |
| Mar 31, 2024 | 12.70 Mn |
| Dec 31, 2023 | -8.47 Mn |
| Dec 31, 2023 | -8.47 Mn |